AroCell: Comments on the Q2 report - Redeye

Redeye comments on the Q2 report and shortly discusses the two major events during and after the quarter, setting a new direction for AroCell. It has been a turbulent couple of months for the company and the stock, and we await a communicated new strategy with the IDL Biotech merger before we present a more detailed review of the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/819964/arocell-comments-on-the-q2-report?utm_source=finwire&utm_medium=RSS